Skip to main content

FDA approves new Dysport indication


SILVER SPRING, Md. — The Food and Drug Administration has approved a new indication for Ipsen Biopharmaceuticals’ Dysport (abobotulinumtoxinA), the company announced Monday. The drug can now be used to treat lower limb spasticity in pediatric patients ages 2 years and older. 


"This approval means that, for the first time, physicians have a FDA-approved botulinum toxin with recommended dosing guidance for the treatment of children two years of age and older with lower limb spasticity based on a large registrational study," said Dr. Ann Tilton, professor of clinical neurology and chief of the section of child neurology at Louisiana State University School of Medicine.


The drug comes with a boxed warning stating that the effects of the botulinum toxin may spread from the injection area to other areas of the body, causing symptoms akin to those of botulism. 


This ad will auto-close in 10 seconds